Global Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market is segmented By Treatment Type (Standard Treatment, Advance Treatment), By Drugs (Ibrutinib, Rituximab, Venetoclax, Umbralisib, BGB-3111, Acalabrutinib, Zydelig, Oprozomib), By Route of Administration (Oral, Parenteral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Overview
The Global Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market report analyzes the market size, shares, recent trends, competitive intelligence, and future market outlook for this rare type of non-Hodgkin's lymphoma. The market is driven by the increasing prevalence of Waldenstrom macroglobulinemia, advancements in diagnostic technologies, and the development of innovative therapies in Europe is growing. Key players in the global Waldenstrom Macroglobulinemia market include Johnson & Johnson, AbbVie Inc., Amgen Inc., Roche Holdings AG, and other prominent players operating in the market.
Waldenstrom macroglobulinemia (WM) is one type of non-Hodgkin lymphoma (NHL). The cancer cells make large amounts of an abnormal protein (called macroglobulin). It is also known as lymphoplasmacytic lymphoma.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Summary
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Treatment Type, By Drugs, By Route of Administration, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For more insights - Download the Sample
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Dynamics
The Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market growth is driven by the increasing incidence of Waldenstrom's macroglobulinemia cases, ongoing clinical trials conducted by many pharmaceutical companies, increase special designation from the regulatory authorities, high demand for novel therapy and huge financial support to the researchers for developing novel intervention is enhancing the market growth.
The increasing prevalence of Waldenstrom's macroglobulinemia cases is expected to drive growth in the forecast period
The growing incidence of Waldenstrom macroglobulinemia cases globally is expected to boost market growth. For instance, according to the statistics published in the U.S. Department of Health & Human Services, it was estimated around 3 per million people are affected with Waldenstrom macroglobulinemia every year in the United States. Each year, an estimated 1,000 to 1,500 adults in the United States are diagnosed with the disease. As per the same source, 8247 males and 4123 females were suffering from Waldenstrom’s Macroglobulinemia in 2017 in the US.
Ongoing-clinical trials conducted by pharmaceutical companies are expected to drive growth in the forecast period
For instance, AstraZeneca conducting a Phase II trial of bendamustine, rituximab, and the second generation BTK Inhibitor Acalabrutinib in previously untreated Waldenstrom's macroglobulinemia patients is expected to complete by 2030.
Bristol-Myers Squibb developing a Dasatinib drug in patients with Waldenstrom macroglobulinemia (WM) progressing on Ibrutinib is under Phase 1 trial and is expected to complete by 2024.
The high cost of chemotherapy and target therapy is likely to hamper the market growth
The high cost of chemotherapy and target therapy for WM is likely to hinder the market. For instance, according to the Journal of clinical oncology, one month of ibrutinib costs approximately $12000. The cost is $8,640 for one cycle of bendamustine therapy and cyclophosphamide or bendamustine for a total cost of approximately $50,000. Hence, the huge cost of drugs may restrict market growth.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Industry Analysis
COVID-19 Impact on Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Growth
The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted major companies' financial status in the market. The private healthcare sector is one of the sectors, which the COVID-19 pandemic has majorly impacted. The pandemic has negatively impacted the global Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market in various aspects such as research and development, production, and supply of medicines. The pandemic has also affected the growth of pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Segment and Shares
The targeted therapy segment is expected to hold the largest share of this market segment
Targeted therapy blocks the growth and spread of cancer cells and limits damage to healthy cells. Targeted therapy for Waldenstrom macroglobulinemia includes monoclonal antibodies. A monoclonal antibody is one type of targeted therapy. It is directed against a specific protein in the cancer cells, and it does not affect cells that do not have that protein. For instance, anti-CD20 antibodies include obinutuzumab (Gazyva), ofatumumab (Arzerra), and rituximab-abbs (Truxima), Ibrutinib, Bortezomib (Velcade) are mostly used targeted therapy drugs for WM.
The ibrutinib segment is expected to hold the largest share in this market segment
Ibrutinib is a type of targeted therapy called Bruton tyrosine kinase (BTK) inhibitor used to treat mantle cell lymphoma, WM. It acts by blocking B-cell receptor signaling, which drives cells into apoptosis and disrupts cell migration and adherence to protective tumor microenvironments. It also has the advantage of being oral with a single dose per day.
For instance, in August 2019, AbbVie Inc, in collaboration with Janssen Pharmaceutical Companies, received approval from the FDA for Imbruvica ((ibrutinib) in combination with rituximab for the treatment of Waldenstrom’s macroglobulinemia. This approval changes the shifts from standard treatment to new disease-specific treatment for patients with Waldenstrom’s macroglobulinemia across the United States.
The oral segment is expected to hold the largest share in this market segment
The oral segment is expected to hold a dominant position in the Waldenstrom macroglobulinemia market as their variable penetration to different target sites of infection, drug solubility, and extent of protein binding determine the strong effectiveness.
The hospital pharmacies segment is expected to hold the largest share in this market segment
The hospital pharmacies held the largest share of the disposable insulin pump market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies and the prescription for the required dosage also provided by doctors in hospitals is contributing to the growth of this segment.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Geographical Share
North America region holds the largest market share of the global Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market
North America region is expected to serve a dominant position in the global Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market over the forecast period, increasing research and development activities by major market players, increasing incidence of WM cases in the U.S. that drives the demand for WM in the region. For instance, according to the statistics published in the U.S. Department of Health & Human Services, it was estimated that around 3 per million people are affected with Waldenstrom macroglobulinemia every year in the United States.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Companies and Competitive Landscape
The global Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market is highly competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include AbbVie, BeiGene, Amgen, TG Therapeutics, Gilead Sciences, Acerta Pharma BV, Johnson & Johnson Services, Inc, Novartis AG, Seattle Genetics, Inc, Merck & Co., Inc, Xiamen Research Biotechnology Co., Ltd, Shanghai Synchem Pharma Co., Ltd, Shanghai Hanjing Chemicals Co., Ltd, Shenzhen Excellent Biotech Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in July 2018, BeiGene received Fast Track designation from the FDA for zanubrutinib (formally known as BGB-3111), Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of Waldenström macroglobulinemia. With Fast Track designation for zanubrutinib accelerates the review timelines and enhances interactions with the FDA, which can bring this potentially disease-modifying drug for patients with Waldenström’s macroglobulinemia as quickly as possible.
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market Key Companies to Watch
Amgen Inc
Company Overview: Amgen (Applied Molecular Genetics Inc.) is established in Thousand Oaks, California, on April 8, 1980, and is one of the world's leading biotechnology companies. It is a values-based company deeply rooted in science and innovation to transform new ideas and discoveries into medicines for serious illnesses. Amgen's subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving identifying and validation human disease targets.
Product Portfolio: The Company’s portfolio comprised of include six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation.
Key developments: Amgen and Janssen were together conducting Phase 3 trials to evaluate the efficacy of the Carfilzomib drug in combination with Ibrutinib in Waldenstrom's macroglobulinemia (CZAR-1) patients.
Why Purchase the Report?
- Visualize the composition of the Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market segmentation by treatment, drugs, route of administration, distribution channel, and region highlighting the key commercial assets and players.
- Identify commercial opportunities in the Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
The global Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) market report would provide access to an approx. 69 market data tables, 65 figures, and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
